$36.8 million for Parkinson’s disease


The Liberal Government is making a significant investment of $36.8 million for Parkinson’s disease research through the Garvan Institute’s Australian Parkinson Mission and in Parkinson’s nurses to improve the lives of people living with the disease, and ultimately, to find a cure.

Federal Member for Peace, Christian Porter, said Parkinson’s disease is recognised as the second most common neurodegenerative disorder in Australia.

“More than 100,000 Australians endure the progressive and debilitating symptoms of Parkinson’s disease – and without a medical breakthrough, this number is expected to double in the next 15 years,” Mr Porter said.

“Our Government is providing $30 million over five years to the Garvan Institute of Medical Research to trial promising drugs to reduce the progression of the disease and allow people in Pearce to live in their homes longer.”

The $30 million in funding comes from the Liberal Government’s landmark Medical Research Future Fund – an endowment fund providing a sustainable source of funding for vital medical research. 

A further $6.8 million over four years will be provided to Primary Health Networks to improve access to specialised nursing care in the community for people living with movement disorders, including Parkinson’s disease.

“Nurses play a critical role in preventing and managing chronic disease and in improving timely access to health care,” Mr Porter said. 

“The specialist nurses would fulfil a range of roles including providing clinical care to patients, coordinating timely access to community based care to manage acute and chronic health problems and delivery of education and information.”

The Australian Parkinson’s Mission is an international research collaboration between the Garvan Institute of Medical Research, Shake it Up Australia Foundation, The Cure Parkinson’s Trust, Michael J Fox Foundation and Parkinson’s Australia.

A successful Australian Parkinson’s Mission will mean that Australian patients and their families will be the first to benefit from the future of precision medicine for Parkinson’s.

The mission will be rolled out nationally through leading capital city centres and extended into regional Australia, where possible, via a hub and spoke model